Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer
Status:
Withdrawn
Trial end date:
2021-06-14
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine in an exploratory manner the objective
overall response rate to ponatinib in the treatment of patients with advanced or metastatic
MTC previously treated with cabozantinib or vandetanib who have tumors with
rearranged-during-transfection (RET) mutations and have tumors without RET mutations.